Diamyd Financial Statements From 2010 to 2024
| DMN Stock | EUR 1.07 0.01 0.94% |
Check Diamyd Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Diamyd Medical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Diamyd financial statements analysis is a perfect complement when working with Diamyd Medical Valuation or Volatility modules.
Diamyd |
Diamyd Medical AB Company Shares Outstanding Analysis
Diamyd Medical's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Diamyd Medical Shares Outstanding | 76.93 M |
Most of Diamyd Medical's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diamyd Medical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Diamyd Medical AB has 76.93 M of shares currently outstending. This is 57.39% lower than that of the Healthcare sector and 28.01% lower than that of the Biotechnology industry. The shares outstanding for all Germany stocks is 86.55% higher than that of the company.
Diamyd Medical AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Diamyd Medical's current stock value. Our valuation model uses many indicators to compare Diamyd Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Diamyd Medical competition to find correlations between indicators driving Diamyd Medical's intrinsic value. More Info.Diamyd Medical AB is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Diamyd Medical's earnings, one of the primary drivers of an investment's value.About Diamyd Medical Financial Statements
Diamyd Medical stakeholders use historical fundamental indicators, such as Diamyd Medical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Diamyd Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Diamyd Medical's assets and liabilities are reflected in the revenues and expenses on Diamyd Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Diamyd Medical AB. Please read more on our technical analysis and fundamental analysis pages.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. DIAMYD MEDICAL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.